Oct. 13, 2008 — Rubicon Genomics, Inc. today announced an agreement with SAIC-Frederick to amplify DNA samples for The Cancer Atlas Genome Project. Rubicon Genomics was selected to amplify and standardize total genomic DNA from 3,000 tissue and blood samples from cancer patients. The Rubicon GenomePlex™ Whole Genome Amplification technology was judged best to amplify clinical DNA samples to the constant concentration and quality necessary for reproducible and accurate analysis using microarrays and PCR. The amplified DNA libraries will be deposited into the International Genomics Consortium Biospecimen Research Core as a renewable resource to be shared among international researchers to completely characterize the genomes of patients with three types of cancer. Their studies will help understand the causes of cancer, as well as how to detect and treat the diseases.

Jan. 22, 2007 — Rubicon Genomics, Inc. today announced a Collaboration Agreement with OncoMethylome Sciences for the identification of biomarkers for early detection of cancer. Rubicon plans to use its MethylPlex™ platform to carry out the marker identification analysis. As part of the agreement, Rubicon granted an option to OncoMethylome for licensing markers resulting from the collaboration. This is the second such marker identification agreement between the two companies, and OncoMethylome Sciences has already licensed a set of markers from Rubicon.

Dec. 13, 2006 — Sigma-Aldrich (Nasdaq: SIAL), a leading $1.7 billion Life Science and High Technology company, is pleased to announce an exclusive licensing agreement with Rubicon Genomics to further develop and commercialize their TransPlex(TM) Whole Transcriptome Amplification (WTA) technology. The TransPlex technology is the fastest, most sensitive and robust method available for amplifying total RNA from a variety of sample sources such as animals, plants, and microorganisms. Under the terms of the agreement, Rubicon retains all rights to TransPlex for molecular diagnostics.

Feb. 27, 2006 — Rubicon Genomics today announced the formation of a new Scientific Advisory Board to support its recent advances in cancer molecular diagnostics.

Feb. 17, 2006 — Sigma-Aldrich (Nasdaq: SIAL), a leading $1.7 billion Life Science company, is pleased to announce a new licensing agreement with Rubicon Genomics that allows Sigma to offer GenomePlex(R) Whole Genome Amplification (WGA) kits to service providers. Under this agreement, Sigma-Aldrich may sell GenomePlex kits to companies offering Whole Genome Amplification Services, thus expanding the service market to archived samples, FFPE and single cells. Rubicon Genomics will retain all rights to WGA for molecular diagnostics, and will continue its existing service business.

Feb. 10, 2006 — Sigma-Aldrich (Nasdaq: SIAL), a leading Life Science and High Technology company, is pleased to announce the launch of GenomePlex® Single Cell Whole Genome Amplification (WGA) Kit.

Oct. 31, 2005 — Rubicon Genomics, Inc. today announced a multi-year Research and Option Agreement with Abbott Molecular, a division of Abbott, to develop and commercialize its MethylPlex™ methylation detection technology for diagnosis and prognosis of cancer.

Sept. 8, 2005 — Rubicon Genomics, Inc., announced the launch of its TransPlex™ whole transcriptome amplification (WTA) kit for amplification of nanogram quantities of RNA from fresh and formalin-fixed tissue. The TransPlex kits have been extensively tested by independent academic and pharmaceutical laboratories, and proven to faithfully reproduce expression patterns even for formalin-fixed biopsies that are more than 10 years old. In less than four hours, 10 nanograms of RNA can be amplified into 10 micrograms of stable cDNA product without detectable 3’ bias or background.

July 21, 2005 — Rubicon Genomics, Inc. today announced an agreement with the Genome Institute of Singapore to use Rubicon molecular diagnostics technology to recover genetic information from clinical serum samples for a large study of the immune response to vaccination against the hepatitis B virus.

Feb. 7, 2005 — Rubicon Genomics, Inc. announced today that James J. Koziarz, Ph.D. has joined its Board of Directors. Dr. Koziarz most recently served as Corporate Vice President, Hepatitis/Retrovirus Research and Development of Abbott Laboratories.

Jan. 11, 2005 — Rubicon Genomics announced today that Timothy M. Mayleben has joined its Board of Directors. Mr. Mayleben most recently served as Chief Operating Officer and Chief Financial Officer of Esperion Therapeutics, Inc., a biopharmaceutical company acquired by Pfizer, Inc. in 2004.

Jan. 4, 2005 — As it concentrates on the development of cancer diagnostics, Rubicon Genomics received $250,000 in the first close of a bridge financing in December, President and Chief Executive Fred Beyerlein told VentureWire.

Dec. 14, 2004 — **

Oct. 4, 2004 — Sigma-Aldrich (NASDAQ: SIAL), a leading Life Science and High Technology company, is pleased to announce a licensing agreement with Rubicon Genomics, a molecular diagnostics company known for development of the GenomePlex™ Whole Genome Amplification (WGA) technology, a highly sensitive, accurate, and proprietary method of amplifying total DNA from any organism. The licensing agreement grants Sigma-Aldrich exclusive world-wide rights to GenomePlex for the production and sale of kits to the research market. Rubicon retains all rights to the technology for its core market, molecular diagnostics, as well as for service. GenomePlex customers will still be able to order kits via the Rubicon website until the Sigma-Aldrich kits are released in the coming months.

Aug. 6, 2003 — Ann Arbor, MI, August 6, 2003 -- Rubicon Genomics, Inc. today announced an agreement with The Wellcome Trust Sanger Institute, in Hinxton, UK, to amplify DNA for genetic studies of obesity and type 2 diabetes.

Feb. 10, 2003 — Ann Arbor, MI, February 10, 2003 -- Rubicon Genomics, Inc. today announced the launch of the company’s service business using its OmniPlex™ whole genome restoration (WGR) to recover genetic information from previously unusable genetic materials. Rubicon’s proprietary in vitro method restore large amounts of genetic information from very small amounts of degraded DNA has powerful applications in gene-based target discovery, drug development, diagnostics, and forensics.

Dec. 16, 2002 — Ann Arbor, MI, December 16, 2002 -- Rubicon Genomics, Inc. today announced the launch of the company’s service business using its OmniPlex™ whole genome amplification (WGA) technology. Rubicon’s proprietary in vitro method to convert very small amounts of genomic DNA into OmniPlex PCR-amplifiable libraries, have powerful applications in gene-based target discovery, drug development, diagnostics and forensics.